Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation – a Comparison of Eculizumab Therapy and Conventional Therapy

We report the results of a single center analysis of a cohort of 39 patients treated between 1997 and 2016 for transplantion –associated thrombotic microangiopathy. We evaluated two subgroups of patients: 24 patients treated between 1997 and 2014 who received conventional therapy and 15 patients who were treated with the complement–inhibiting monoclonal antibody eculizumab between 2014 and 2016. The conventional thera py group was predominantly treated with defibrotide alone or in combination with plasmapheresis or rituximab.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research